MADISON, Wis. , June 6, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced that, after an extensive review over the last several months, including the evaluation of numerous potential financing partners, it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2026 (the "Notes") to exchange an aggregate of $82.0 million principal amount of Notes for an aggregate of 8,881,579 shares of the Accuray's common stock (the "Shares").
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
MADISON, Wis. , May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025.
Medical - Specialties Industry | Healthcare Sector | Ms. Suzanne Winter M.B.A. CEO | XSTU Exchange | US0043971052 ISIN |
US Country | 987 Employees | - Last Dividend | - Last Split | - IPO Date |
Accuray Incorporated is a leading innovator in the field of precision radiation oncology, providing advanced radiosurgery and radiation therapy systems worldwide. Founded in 1990 and based in Madison, Wisconsin, the company's pioneering solutions are designed to enhance cancer treatment by targeting tumors with high precision. Accuray’s global reach extends across the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, China, and the rest of the Asia Pacific region. The company is committed to improving patient outcomes by offering cutting-edge technology for the treatment of primary and metastatic tumors outside the brain, among other applications. In addition to developing and manufacturing its products, Accuray Incorporated offers a comprehensive range of support services including post-contract customer support, installation, training, and professional services to ensure the effective use and maintenance of its systems.
This innovative robotic stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) system is at the forefront of Accuray’s offerings. The CyberKnife System is designed for the treatment of primary and metastatic tumors located outside the brain. It is particularly effective for tumors on or near the spine and in regions such as the breast, kidney, liver, lung, pancreas, and prostate. Utilizing robotic technology, the system delivers highly precise treatment, minimizing damage to surrounding healthy tissue.
The TomoTherapy and Radixact Systems represent a significant advancement in the delivery of radiation therapy, enabling clinicians to perform ultra-precise treatments for a wide range of cancers. These systems feature integrated radiation treatment planning, delivery, and data management capabilities. The high level of precision and efficiency allows for treating approximately 50 patients per day, making it a pivotal tool in high-volume treatment centers.
Accuray’s iDMS Data Management System is designed to enhance the efficiency of treatment planning and delivery by providing a fully integrated suite for managing patient data and treatment plans. This system streamlines the workflow, facilitating a more seamless operation from planning through treatment.
The Accuray Precision Treatment Planning System is tailored to support the detailed and complex planning required for delivering precise radiation therapy. By offering sophisticated data management and planning tools, this system aids clinicians in creating optimized treatment strategies for their patients.
In addition to its pioneering technology, Accuray Incorporated provides a comprehensive suite of professional services. These include post-contract customer support, which ensures that all systems are maintained to the highest standards, as well as installation and training services. Through these offerings, Accuray empowers healthcare providers to maximize the benefits of its systems for patients, thereby enhancing treatment outcomes and operational efficiency.